CHICAGO (Reuters) - Eli Lilly and Co. on Thursday said it will add strong warnings to its label for Strattera, used to treat attention-deficit/hyperactivity disorder, including the risk of suicidal thoughts among children and adolescents.
I had personal evidence about SSRI's, but this one caught me by surprise.
